GB2462005A - Wound dressing material - Google Patents
Wound dressing material Download PDFInfo
- Publication number
- GB2462005A GB2462005A GB0912815A GB0912815A GB2462005A GB 2462005 A GB2462005 A GB 2462005A GB 0912815 A GB0912815 A GB 0912815A GB 0912815 A GB0912815 A GB 0912815A GB 2462005 A GB2462005 A GB 2462005A
- Authority
- GB
- United Kingdom
- Prior art keywords
- wound dressing
- dressing material
- honey
- material according
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000463 material Substances 0.000 title claims abstract description 104
- 235000012907 honey Nutrition 0.000 claims abstract description 61
- 239000000203 mixture Substances 0.000 claims abstract description 50
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 33
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 30
- 239000003349 gelling agent Substances 0.000 claims abstract description 29
- 239000003906 humectant Substances 0.000 claims abstract description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 20
- 239000008103 glucose Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 18
- 240000003553 Leptospermum scoparium Species 0.000 claims abstract description 14
- 235000016887 Leptospermum scoparium Nutrition 0.000 claims abstract description 14
- 239000007787 solid Substances 0.000 claims abstract description 13
- 229930091371 Fructose Natural products 0.000 claims abstract description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 7
- 239000005715 Fructose Substances 0.000 claims abstract description 7
- 229920005862 polyol Polymers 0.000 claims abstract description 6
- 150000003077 polyols Chemical class 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims description 15
- 239000006188 syrup Substances 0.000 claims description 11
- 235000020357 syrup Nutrition 0.000 claims description 11
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 3
- 208000027418 Wounds and injury Diseases 0.000 description 92
- 206010052428 Wound Diseases 0.000 description 91
- 230000035876 healing Effects 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 238000005469 granulation Methods 0.000 description 7
- 235000013772 propylene glycol Nutrition 0.000 description 7
- 229960004063 propylene glycol Drugs 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 210000000416 exudates and transudate Anatomy 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000651 myofibroblast Anatomy 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000035404 Autolysis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000257303 Hymenoptera Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 230000028043 self proteolysis Effects 0.000 description 2
- -1 solidifiers Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 239000003357 wound healing promoting agent Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GZCGUPFRVQAUEE-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxyhexanal Chemical compound OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N 3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- GKFPPCXIBHQRQT-UHFFFAOYSA-N 6-(2-carboxy-4,5-dihydroxy-6-methoxyoxan-3-yl)oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(OC)C(C(O)=O)O1 GKFPPCXIBHQRQT-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- QMGYPNKICQJHLN-UHFFFAOYSA-M Carboxymethylcellulose cellulose carboxymethyl ether Chemical compound [Na+].CC([O-])=O.OCC(O)C(O)C(O)C(O)C=O QMGYPNKICQJHLN-UHFFFAOYSA-M 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 description 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- HAIWUXASLYEWLM-UHFFFAOYSA-N D-manno-Heptulose Natural products OCC1OC(O)(CO)C(O)C(O)C1O HAIWUXASLYEWLM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 235000017367 Guainella Nutrition 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 235000017765 Leptospermum flavescens Nutrition 0.000 description 1
- 240000008186 Leptospermum polygalifolium Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- HAIWUXASLYEWLM-AZEWMMITSA-N Sedoheptulose Natural products OC[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@](O)(CO)O1 HAIWUXASLYEWLM-AZEWMMITSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001320 aldopentoses Chemical class 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 150000008266 deoxy sugars Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- UQPHVQVXLPRNCX-UHFFFAOYSA-N erythrulose Chemical compound OCC(O)C(=O)CO UQPHVQVXLPRNCX-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- CJJCPDZKQKUXSS-JMSAOHGTSA-N fuculose Chemical compound C[C@@H]1OC(O)(CO)[C@H](O)[C@@H]1O CJJCPDZKQKUXSS-JMSAOHGTSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 150000002386 heptoses Chemical class 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 150000002454 idoses Chemical class 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 150000002581 ketopentoses Chemical class 0.000 description 1
- 150000002586 ketotetroses Chemical class 0.000 description 1
- 150000002588 ketotrioses Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- HSNZZMHEPUFJNZ-SHUUEZRQSA-N sedoheptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-SHUUEZRQSA-N 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/07—Stiffening bandages
- A61L15/12—Stiffening bandages containing macromolecular materials
- A61L15/125—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
A wound dressing material has the form of a pliable solid, and comprises honey (1 to 49 wt%), an additional monosaccharide (1 to 45 wt%), a humectant (1 to 25 wt%) and a gelling agent (1 to 25 wt%). The honey may be Manuka honey. The additional monosaccharide may be either glucose or fructose. The humectant may be a polyol such as propylene glycol. The material may be prepared by a method that involves forming a first mixture comprising honey and monosaccharide, forming a second mixture comprising humectant and gelling agent, combining the first mixture and the second mixture, and causing or allowing the composition to cure.
Description
I
Title -Honey wound dressing The present invention relates to wound dressings containing honey and their medical application.
Wound healing is a complex process involving the integration and orchestration of a number of different biological events. The ultimate aim of the process is to repair the barrier properties of the skin as quickly as possible so that it can continue to perform its key functions in protection of the body from pathological infection and ionising radiation while also regulating body temperature and containing the internal organs. Normal wound healing is often separated, for the purposes of understanding, into three phases, known as Inflammation, Granulation and Maturation. These phases are intrinsically linked to one another but quite often the boundaries of each phase will overlap with one another, adding to the complexity of the process.
The inflammation stage includes the blood clotting processes, the recruitment of macrophages to the wound site, the initiation of the inflammatory pathways and the initiation of keratinocyte reepithelialisation. The granulation phase, which follows, involves the phenotypic alteration of fibroblasts in the dermal layer to myofibroblasts, and further keratinocyte reepithelialisation. The myofibroblasts migrate into the denuded wound space and produce the extracellular matrix (ECM) protein (including collagen, elastin, and fibronectin) that makes up the substance material of the repair. Myofibroblasts are also known to contract the wound boundaries thereby minimising the wound area required for healing. Often this contraction is painful and can continue into the maturation phase, particularly in the development of hypertrophic scars. During maturation a number of proteases are present within the wound (such as matrix metalloproteases and tissue inhibitors of matrix metalloproteases). These degrade unwanted tissue and restore the protein balances, thereby restoring the appearance of the scar to that of normal skin.
Different wound types such as normal incisional or burn wounds have different stage lengths. For instance, burn wounds have a long granulation phase, due to the extensive wide area cell death. Scars from burn wounds are often hypertrophic and the maturation phases can take a lifetime to complete. Ulcerated wounds on the other hand have a number of compounding factors leading to increased inflammation and granulation phases. Leg ulceration is most commonly caused by venous hypertension resulting from valvular incompetence in the superficial, deep or perforating veins. Sustained venous hypertension causes swelling, restricted blood flow and damage to the skin and other tissues. The healing of ulcerated wounds is further often compounded by a lack of mobility in the patient which leads to a lack of venous return and a build-up of free radicals in the lower limbs. These cause tissue damage and a small bruise can very rapidly develop into an ulcer.
In the UK, chronic wounds represent a significant burden to patients and the National Health Service (NHS). Some 200,000 patients in the UK have a chronic wound. The impact on their quality of life is well documented. Common symptoms of ulceration include pain, exudate and odour, and these symptoms are frequently associated with poor sleep, loss of mobility and social isolation. The cost to the NHS of caring for patients with a chronic wound is conservatively estimated at �2.3bn-3.1 bn per year (at 2005-2006 costs), around 3% of the total estimated out-turn expenditure on health (E89.4bn) for the same period. With proper diagnosis and treatment, much of this burden should be avoidable.
Commonly used wound dressings, for efficacy, should maintain a moist environment at the wound interface, remove excess exudate without allowing strike through' to the surface of the dressing, provide thermal insulation and mechanical protection, act as a barrier to micro-organisms, allow gaseous exchange, be non-adherent and easily removed without trauma, leave no foreign particles in the wound, be non-toxic and be non-allergenic and non-sensitising. No single dressing is appropriate for all wound types and all stages of healing. The following types of dressing are examples of some most commonly used.
Hydrocolloids, eg Granuflex� (ConvaTec Ltd), consist of a matrix of cellulose and other gel-forming agents such as gelatine and pectin. They are occlusive and therefore are mostly applicable where infection, particularly with anaerobic organisms, is not present. They promote autolysis and aid granulation, but as they can remain in place for up to a week, over-granulation can occur.
Alginates, eg Kaltostat� (ConvaTec Ltd), consist of calcium and sodium salts of alginic acid obtained from seaweed. They are highly absorbent and useful for medium to heavily exuding wounds. Unfortunately, secondary covering is required as the dressing forms a gel in contact with wound exudate.
Foam dressings, eg Lyofoam� (Seton Healthcare Group plc), consist of foam-type material and are useful for moderately exudating wounds. They prevent strike through' of exudate to the wound surface and essentially deslough the wounds by maintaining a moist environment.
Hydrogels, eg IntrasiteTM Gel (Smith and Nephew Group plc), consist of dressings with a high water content to create a moist wound surface. This debrides wounds by hydration and promotion of autolysis and the dressing will absorb a light exudate. Unfortunately they are not appropriate for heavily exudating wounds.
Debriding agents consist of enzymic or acid treatments to remove eshcar and necrotic tissue. They do not maintain a moist environment, need frequent changes and they damage granulation tissue. Although they debride the wound, they delay healing.
Alternatives to the commonly used dressings have been sought because of the increasing requirement for the use of alternative therapies, especially as the development of antibiotic resistance in bacteria is becoming a major problem. Sugar dressings have been developed in the past for their ability to form pastes that can be applied to wounds, and for their inherent ability to cause osmotic shock to bacteria within the wound and thereby prevent bacterial growth. A more complex but more traditional alternative has been to use honey in dressings. Honey is a mixture of sugars, water and other active ingredients such as vitamin C, catalase and chrysin, that are thought to act as antioxidants (Gheldof et a!., 2002). As such, it has much greater activity than sugar alone and has been shown to support wound healing through its anti-inflammatory action, its natural antibacterial properties, its debriding action and its stimulatory effect on granulation and epithelialisation. In fact, honey has been shown to have considerable wound and ulcer healing capacity and strong antimicrobial capacity even in moist healing environments.
Unlike other topical antiseptics, honey causes no tissue damage and in animal studies it has been demonstrated histologically that it actually promotes the healing process. It has a direct nutrient effect as well as drawing lymph out of the cells by osmosis. The stimulation of healing may also be due to the acidity of honey. The osmosis creates a solution of honey in contact with the wound surface which prevents the dressing sticking, so there is no pain or tissue damage when dressings are changed. There is much anecdotal evidence to support its use, but randomised controlled clinical trials have shown that honey is more effective than silver sulfadiazine and a polyurethane film dressing (OpSite�, Smith and Nephew Group plc) for the treatment of burns.
Unfortunately, honey has some drawbacks presently as a wound treatment. Its natural fluidity at body temperature is problematic for retaining sufficient amounts within the wound space. One attempt to address this problem is described in U52007/0265585A, which discloses the use of a housing for covering at least a portion of a wound and for sealing to a body surface of a patient. The housing includes a liquid-retention chamber for retaining the honey to avoid it running away; however, the device is cumbersome and relatively non-adaptable to different wound sizes.
Soaking honey with absorbent materials such as gauze, in a dressing to be applied to the wound is an alternative solution, but a rather messy one. The untidiness is further compounded by the fact that the dressing is then held in place by a further covering, which is cumbersome. This risks further infection due to secondary occlusion. Furthermore, the use of gauze or foam has additional complications in that often fragments are left behind when the material is removed.
To overcome these drawbacks, honey has been combined with various gelling agents such as alginate, as described by EP1237561, or with starch, glycerol, acrylamide or carboxymethyl cellulose (CMC). EP1237561 discloses medical compositions comprising more than 50% honey, that are in the form of formable or pliable solids.
However, it has been found that adding just a gelling agent (such as alginate) to honey does not enable sufficient control of the gelling process for it to be possible, on a commercially viable scale, to create sheets of material that are uniform and consistent in nature. Uniformity and consistency are important qualities for wound dressings so as to confer similar properties on the healed structure and for them to fulfil their requirement as protective dressings. It has been found that adding just a gelling agent results in agglutination, whereby the honey is formed rapidly into liquid viscous clumps, which are sticky and not useable in manufacturing processes involving extrusion or moulding. This means that the processes described in the prior art do not enable mass production of honey-based wound dressings in the form of pliable sheets and the like, particularly in the case of large area dressings (such as those required for whole body burns, open heart surgery or graft treatment).
There has now been devised an improved wound dressing which overcomes or substantially mitigates the above-mentioned and/or other problems associated with
the prior art.
According to a first aspect of the invention there is provided a wound dressing material in the form of a pliable solid, the material comprising from I to 49 wt% honey, from I to 45 wt% additional monosaccharide, from I to 25 wt% humectant and from 1 to 25 wt% gelling agent.
The wound dressing material according to the invention is advantageous principally because the mixture of honey, additional monosaccharide (eg glucose syrup), humectant (eg propylene glycol) and gelling agent (eg carboxymethyl cellulose (CMC)), can be formed into a sheet, layer or pliable putty. The dressing material is suitable for mass production as a sheet material whereby the physical and compositional qualities of the dressing are replicable, clean and sterile. The messiness and uncontrollable containment of the honey, that is conventionally associated with honey soaked gauzes, is no longer present.
The wound dressing material according to the invention is further advantageous because by altering the composition, the consistency of the dressing can be altered and therefore the material can release honey into the wound space over a period of hours, days or weeks, allowing for a sustained efficacy. In so doing, the wound dressing material according to the invention can draw exudate from the wound whilst maintaining a moist environment at the wound site over a long period of time.
Honey may be present in the wound dressing material according to the invention at a level in the range of I to 49 wt%. In some embodiments, the honey is present at a level in the range of 10 to 43 wt% or in the range of 20 to 38 wt%. In the presently most preferred compositions, the honey is present at a level of about 32 wt%.
Being a natural substance, honey is of variable composition, and this results in some variability in the characteristics and performance of the dressings that incorporate it. The selection of Manuka honey from bees that have gathered pollen from the flowers of the Manuka tree (Leptospermum scoparium) is particularly preferred because it is believed to contain an additional antibacterial phytochemical component. The Manuka tree is indigenous to New Zealand and Manuka honey is widely produced in that country. Another form of honey that may be particularly useful in the present invention is that produced by bees that have gathered pollen from the flowers of Leptospermum polygalifolium, which is related to the Manuka tree and is native to Australia. The most preferred honey for use in the present invention is "UMF Manuka Honey", also called Active Manuka Honey. Active Manuka honey is sold with its activity rated on a "UMF" scale, the UMF (Unique Manuka Factor) being the equivalent concentration of phenol with the same antibacterial activity against Staphylococcus aureus (ie UMF 15 = 15% phenol). Preferred compositions according to the invention comprise Manuka honey with a UMF rating greater than 10, more preferably UMF 12 or above.
The wound dressing material comprises an amount of one or more additional monosaccharides. By this is meant an amount of monosaccharide over and above those present in the honey. Suitable monosaccharides may include ketotriose, aldotriose, ketotetrose, erythrulose, erythrose, threose, ketopentose, ribulose, xylulose, aldopentose, ribose, arabinose, xylose, lyxose, deoxyribose, hexoses, ketohexose, psicose, fructose, sorbose, tagatose, aldohexose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, deoxy sugar, fucose, fuculose, rhamnose, heptose and sedoheptulose. Mixtures of monosaccharides may be used, eg mixtures of glucose and fructose.
The additional monosaccharide may be incorporated into the wound dressing material as a dry solid, but is more preferably utilised in the form of a concentrated aqueous solution or syrup. Typically, such a solution or syrup may contain more than 50 wt% of monosaccharide, eg more than 60 wt% or more than 70 wt%.
The wound dressing material comprises preferably glucose syrup. The glucose syrup may be present in the wound dressing material according to the invention at a level in the range of I to 45 wt%. In some embodiments, the glucose syrup is present at a level in the range of 10 to 43 wt%, or more preferably in the range of 20 to 38 wt%. In the presently most preferred compositions, the glucose syrup is present at a level of about 32 wt%.
The inclusion of glucose syrup into the wound dressing according to the invention is advantageous primarily because the it improves the smoothness and pliability of the The invention thus further provides a wound dressing material in the form of a pliable solid, the material comprising from I to 49 wt% honey, from I to 49 wt% of an additional monosaccharide, and from I to 25 wt% gelling agent.
As in the first aspect of the invention, such a wound dressing material may further comprise from I to 25 wt% of a humectant.
A variety of types and forms of glucose can be used in the wound dressing material according to the invention. As noted above, the glucose can be in the form of a liquid, syrup, or solution in water. Alternatively, the glucose can be in the form of a solid or semi solid suitable for mixing with a solution for preparation before addition into the wound dressing material. The glucose may be admixed with one or more other monosaccharides, eg fructose. In preferred embodiments of the invention, the additional monosaccharide comprises a major proportion (eg more than 70, more than 80 or more than 85 wt%) of glucose and a minor proportion (eg less than 30, less than 20 or less than 15 wt%) of fructose. The glucose that may be used in the composition according to the invention can be in the so called "D" configuration or the "L" configuration, ie the two stereoisometric forms of the glucose molecule.
The wound dressing material according to the invention may comprise one or more of a variety of gelling agents. A gelling agent is an additive used to thicken and stabilize the material. Suitable gelling agents for the purposes of the invention include jellies, stabilizers, solidifiers, thickening agents, natural gums, starches, pectins, agar-agar, gelatine, various polysaccharides, various proteins, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, polysaccharides from brown algae, agar, polysaccharides obtained from red seaweeds, carrageenan, locust bean gum, natural gum from the seeds of the Carob tree, pectin, polysaccharides obtained from apple or citrus-fruits and gelatine. Preferably the gelling agent is a synthetic cellulose derivative. Preferably the gelling agent is carboxymethyl cellulose (CMC) or a salt thereof. CMC or salts thereof may be included in the composition in a range from Ito 25 wt% CMC. In some embodiments, the CMC is present at a level in the range of 5 to 20 wt%, or in the range of 10 to 17 wt%. In the presently most preferred compositions, the CMC is present at a level of about 12 wt%.
The composition according to the first aspect of the invention further comprises a humectant, ie an ingredient that attracts or retains moisture. Examples of humectants that may be suitable for use in the invention include glycerine, glyceryl triacetate, various polyols such as sorbitol, xylitol, maltitol, polymeric polyols such as polydextrose or other natural extracts such as quillaia, lactic acid or urea. Preferably the humectant is a polyol, in particular a diol or triol. Most preferably the humectant is propylene glycol (also known as monopropylene glycol, propane-I,2-diol, propylene glycol or propyleneglycol). Propylene glycol may be present in the composition according to the invention at a level in the range of I to 25 wt%. In some embodiments, the propylene glycol is present at a level in the range of 10 to 25 wt%, or in the range of 15 to 25 wt%. In the presently most preferred compositions, the propylene glycol is present at a level of about 22 wt%.
The wound dressing material according to the invention may comprise additional ingredients to improve its physical properties such as flexibility and adherence. For example, it is desirable for a wound dressing material according to the invention to have some adherence to the skin on application, so that it stays in place, for instance while additional bandages or tapes are secured in order to fasten it in place more permanently. However, it is also desirable that a wound dressing material according to the invention is non-adherent, so that it can be peeled away from the wound without causing damage. The wound dressing material according to the invention may comprise other active ingredients, such as antibiotics, anti-inflammatory agents, and other wound healing agents. Such ingredients may include silver, which is known for its antimicrobial properties.
The wound dressing material of the invention will generally contain a low proportion of water, arising from the water content of the honey and the glucose syrup or the like (if used). Typically, the water content of the wound dressing material will be less than wt%, or less than 5 wt%.
If honey and a gelling agent are mixed together it has been found that setting of the gel is uncontrollable, resulting in agglutination. This does not allow for the end product materials to be shaped into usable or reproducible structures that could be applicable as wound dressings. It has now surprisingly been found that adding humectant enables more control of the gelling process. This then allows the manufacture of a wound dressing material according to the invention with a desired shape and size.
The invention thus further provides a wound dressing material in the form of a pliable solid, the material comprising from I to 70 wt% honey, from I to 25 wt% of a humectant, and from I to 25 wt% gelling agent.
As in the first aspect of the invention, such a wound dressing material may further comprise from I to 45 wt% additional monosaccharide.
It has been found that by preparing a mixture of honey and monosaccharide and a separate mixture of humectant and gelling agent, and then combining the two, the gelling reaction that subsequently occurs is controllable. This allows for mixtures to be manufactured into wound dressing material as sheets or other physical forms such as blocks, cubes, strings, fibres etc. Without using this process the formation of wound dressing material on an industrial scale has been found not to be possible.
Thus, in a second aspect of the invention there is provided a process for the manufacture of a wound dressing material in the form of a pliable solid, the material comprising honey, additional monosaccharide, humectant and gelling agent, which process comprises the steps of: a) providing a first mixture comprising honey and additional monosaccharide, b) providing a second mixture comprising humectant and gelling agent, c) combining the first mixture and the second mixture, c) causing or allowing the composition to cure.
The first mixture may be provided by adding an amount of honey and an amount of monosaccharide to a first container and mixing. Similarly, the second mixture may be provided by adding an amount of humectant and an amount of gelling agent to a second container and mixing. The separation of the two mixtures prevents premature gelling and agglutination. Appropriate amounts of the first and second mixtures are then combined to form a single mixture which is preferably then further mixed for a period of time. The single mixture is then preferably applied to a surface on which the mixture is caused or allowed to cure. Where the finished material is intended to have the form of a sheet, the single mixture is preferably poured and/or spread onto a surface, preferably using a scraper blade or the like to ensure uniform thickness and distribution of the material. The surface to which the mixture is applied is preferably chilled.
Curing of the material to form the wound dressing material according to the invention may be brought about by various means, but preferably involves the application of heat. Most preferably, the material, once spread onto a surface, is exposed to one or more heating elements. A particularly preferred form of heating element is a medium wave Infra Red (IR) source. Such a heating element has been found to be highly controllable, so that the amount of energy delivered can be adjusted as required for the formation of the wound dressing material. Most preferably, the material is transported past the heating element(s), such that the degree of curing can be controlled by varying the time taken for the material to pass the heating element(s).
By altering the speed of passage of the material and the energy provided to the heating element(s), it is possible to control the curing of the material. This is particularly important when dressing materials produced according to the invention are of widely different shapes and sizes.
The wound dressing materials according to the invention may have sufficient strength and integrity to be self-supporting structures. Alternatively, or in addition, the materials may be applied to a flexible scaffold. This may be achieved by spreading the single mixture referred to above onto a scaffold material, eg in the form of a gauze, a foam, a sponge, or the like. When the material cures, it may become intimately bonded to the scaffold structure.
Preferably, individual dressings comprising the wound dressing material of the invention are cut to shape. Such individual dressings may have a backing material applied to one or more of their surfaces. Preferably, this backing material is selected from paper, plastics film, metal foil, non-woven material, or woven material (such as gauze). Preferably the backing material that is applied extends beyond at least one edge of the dressing, to facilitate its removal.
The wound dressings according to the invention are generally packaged as individual units in envelopes that are bacteria-proof. Most preferably, the package is sterilised, most commonly using ethylene oxide or by irradiation with y-radiation.
The wound dressing material according to the invention is useful in the treatment of Thus, in a further aspect of the invention, there is provided the use of a wound dressing material in the form of a pliable solid, the material comprising from I to 49 wt% honey, from I to 45 wt% additional monosaccharide, from I to 25 wt% humectant and from I to 25 wt% gelling agent, as a wound healing agent.
In another aspect of the invention there is provided a method of treating a wound, which method comprises the application to the wound of a wound dressing material in the form of a pliable solid, the material comprising from 1 to 49 wt% honey, from I to wt% additional monosaccharide, from I to 25 wt% humectant and from I to 25 wt% gelling agent.
A wound may be regarded as any injury to living tissue. This may include but is not limited to a type of physical trauma wherein the tissue is torn, broken, pierced, lacerated, cut, punctured and burnt. This may also include but is not limited to a type of physical trauma wherein the tissue is ulcerated, infected, inflamed, infested and necrotic. This may also include but is not limited to situations in which blunt force trauma causes a contusion resulting in a so called "closed wound".
The wound dressing material according to the invention may be prepared in the form of a sheet that is applied to a wound in that form. Alternatively, the material may be formed into any other desired shape suitable for application to a wound, or packing of a wound cavity, ie the material may be used as a putty.
The invention will now be described in greater detail, by way of illustration only, with reference to the following Example.
Example
A honey based wound dressing was prepared as follows: A first mixture of 32.49kg Manuka honey and 32.49kg liquid glucose (approx 77% dry substance, including 8-10% fructose) was prepared.
A second mixture was prepared by dispersing 12.73kg CMC powder in 22.29kg monopropylene glycol.
The first and second mixtures were combined to produce a curable composition with the following composition: 32.49 wt% liquid glucose 32.49 wt% honey 22.29 wt% monopropylene glycol 12.73 wt% CMC The composition was poured onto a moving conveyor belt that was chilled. A spreading knife was used to control the thickness of the material on the belt and suction was applied from underneath so as to hold the material onto the belt as it travelled towards a curing station with heating elements. The heating elements were a number of banks of medium wave Infra Red elements disposed above the conveyor belt, all of which were electronically controlled.
As the wound dressing material passed underneath the banks of IR lamps, the material was cured to form a sheet that was flexible, malleable and of sufficient tensile strength as to avoid breakage during handling. The cured product was then cut to the size required using a cutting blade and then paper backing sheets were applied to both sides. The backing sheets were of greater size than the product, to facilitate removal of the backing sheets.
Claims (28)
- Claims 1. A wound dressing material in the form of a pliable solid, the material comprising from I to 49 wt% honey, from I to 45 wt% additional monosaccharide, from I to 25 wt% humectant and from I to 25 wt% gelling agent.
- 2. A wound dressing according to Claim 1, wherein the honey is Manuka honey.
- 3. A wound dressing according to Claim 2, wherein the honey has a UMF rating greater than 10.
- 4. A wound dressing according to Claim 3, wherein the honey has a UMF rating of 12 or above.
- 5. A wound dressing material according to any preceding claim, wherein the honey is present at a level in the range of 10 to 43 wt%.
- 6. A wound dressing material according to any preceding claim, wherein the honey is present at a level in the range of 20 to 38 wt%.
- 7. A wound dressing material according to any preceding claim, wherein the honey is present at a level of about 32 wt%.
- 8. A wound dressing material according to any preceding claim, wherein the additional monosaccharide is present at a level in the range of 10 to 43 wt%.
- 9. A wound dressing material according to any preceding claim, wherein the additional monosaccharide is present at a level in the range of 20 to 38 wt%.
- 10. A wound dressing material according to any preceding claim, wherein the additional monosaccharide is present at a level of about 32 wt%.
- 11. A wound dressing material according to any preceding claim, wherein the additional monosaccharide comprises glucose.
- 12. A wound dressing material according to any preceding claim, wherein the additional monosaccharide comprises fructose.
- 13. A wound dressing material according to any preceding claim, wherein the additional monosaccharide is employed in the form of a concentrated aqueous solution or syrup.
- 14. A wound dressing material according to any preceding claim, wherein the humectant is present at a level in the range of 10 to 25 wt%.
- 15. A wound dressing material according to any preceding claim, wherein the humectant is present at a level in the range of 15 to 25 wt%.
- 16. A wound dressing material according to any preceding claim, wherein the humectant is present at a level of about 22% wt%.
- 17. A wound dressing material according to any preceding claim, wherein the humectant is a polyol.
- 18. A wound dressing material according to Claim 17, wherein the polyol is propylene glycol.
- 19. A wound dressing material according to any preceding claim, wherein the gelling agent is present in a range from 5 to 20 wt%.
- 20. A wound dressing material according to any preceding claim, wherein the gelling agent is present at a level in the range of 10 to 17 wt%.
- 21. A wound dressing material according to any preceding claim, wherein the gelling agent is present at a level of about 12 wt%.
- 22. A wound dressing material according to any preceding claim, wherein the gelling agent is a synthetic cellulose derivative.
- 23. A wound dressing material according to Claim 22, wherein the gelling agent is carboxymethyl cellulose or a salt thereof.
- 24. A process for the manufacture of a wound dressing material in the form of a pliable solid, the material comprising honey, additional monosaccharide, humectants and gelling agent, which process comprises the steps of a) providing a first mixture comprising honey and monosaccharide, b) providing a second mixture comprising humectant and gelling agent, c) combining the first mixture and the second mixture, c) causing or allowing the composition to cure.
- 25. A process for the manufacture of a wound dressing material according to Claim 24 whereby the wound dressing material is in the form of a sheet.
- 26. A process as claimed in Claim 24 or Claim 25, wherein the wound dressing material is as claimed in any one of Claims I to 23.
- 27. A wound dressing material substantially as hereinbefore described.
- 28. A process for the manufacture of a wound dressing material substantially as hereinbefore described.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0813541.0A GB0813541D0 (en) | 2008-07-24 | 2008-07-24 | Honey wound dressing |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0912815D0 GB0912815D0 (en) | 2009-08-26 |
GB2462005A true GB2462005A (en) | 2010-01-27 |
Family
ID=39737564
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0813541.0A Ceased GB0813541D0 (en) | 2008-07-24 | 2008-07-24 | Honey wound dressing |
GB0912815A Withdrawn GB2462005A (en) | 2008-07-24 | 2009-07-23 | Wound dressing material |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0813541.0A Ceased GB0813541D0 (en) | 2008-07-24 | 2008-07-24 | Honey wound dressing |
Country Status (2)
Country | Link |
---|---|
GB (2) | GB0813541D0 (en) |
WO (1) | WO2010010399A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150030688A1 (en) * | 2013-07-25 | 2015-01-29 | Saint Louis University | Honey and growth factor eluting scaffold for wound healing and tissue engineering |
WO2018162900A1 (en) * | 2017-03-07 | 2018-09-13 | The University Of Sheffield | Wound healing medicament |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10342891B2 (en) | 2013-09-19 | 2019-07-09 | Medline Industries, Inc. | Wound dressing containing saccharide and collagen |
US10086017B2 (en) * | 2013-09-19 | 2018-10-02 | Medline Industries, Inc. | Wound dressing containing polysaccharides |
AU2016298711A1 (en) * | 2015-07-28 | 2018-02-22 | Imbue Nz Ltd | Manuka and/or kanuka honey wet wipes and manuka and/or kanuka oil tissues |
US11090408B2 (en) | 2016-12-06 | 2021-08-17 | The Texas A&M University System | Antimicrobial shape memory polymers |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006321778A (en) * | 2005-05-20 | 2006-11-30 | Kosumedei Seiyaku Kk | Skin restoring composition and skin restoring agent using the same |
US20060275218A1 (en) * | 2003-08-04 | 2006-12-07 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
WO2007030023A1 (en) * | 2005-09-06 | 2007-03-15 | Comvita Limited | A medical composition for treating wounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3827561C1 (en) * | 1988-08-13 | 1989-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
USRE42755E1 (en) * | 1999-12-09 | 2011-09-27 | Apimed Medical Honey Limited | Honey based wound dressing |
NZ505514A (en) * | 2000-06-30 | 2003-02-28 | Bee & Herbal New Zealand Ltd | Method of manufacturing a wound dressing for the application of honey |
WO2007045931A2 (en) * | 2005-10-22 | 2007-04-26 | Brightwake Limited | Compositions and dressings for the treatment of wounds |
-
2008
- 2008-07-24 GB GBGB0813541.0A patent/GB0813541D0/en not_active Ceased
-
2009
- 2009-07-23 GB GB0912815A patent/GB2462005A/en not_active Withdrawn
- 2009-07-23 WO PCT/GB2009/050911 patent/WO2010010399A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060275218A1 (en) * | 2003-08-04 | 2006-12-07 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
JP2006321778A (en) * | 2005-05-20 | 2006-11-30 | Kosumedei Seiyaku Kk | Skin restoring composition and skin restoring agent using the same |
WO2007030023A1 (en) * | 2005-09-06 | 2007-03-15 | Comvita Limited | A medical composition for treating wounds |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150030688A1 (en) * | 2013-07-25 | 2015-01-29 | Saint Louis University | Honey and growth factor eluting scaffold for wound healing and tissue engineering |
WO2018162900A1 (en) * | 2017-03-07 | 2018-09-13 | The University Of Sheffield | Wound healing medicament |
JP2020510701A (en) * | 2017-03-07 | 2020-04-09 | ザ・ユニバーシティ・オブ・シェフィールド | Wound healing drug |
Also Published As
Publication number | Publication date |
---|---|
GB0912815D0 (en) | 2009-08-26 |
WO2010010399A3 (en) | 2010-10-07 |
GB0813541D0 (en) | 2008-08-27 |
WO2010010399A2 (en) | 2010-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schoukens | Bioactive dressings to promote wound healing | |
Zeng et al. | Approaches to cutaneous wound healing: basics and future directions | |
CN108014366B (en) | Marine biological material composite hydrogel dressing and preparation method thereof | |
AU2015246140B2 (en) | Hemostatic Devices | |
CN103599558B (en) | A kind of quick hemostatic dressing and preparation method thereof | |
GB2462005A (en) | Wound dressing material | |
RU149063U1 (en) | ANTI-MICROBIAL ACTION BAND FOR HEALING | |
CN111632190B (en) | Preparation method of medical biogel hemostatic dressing | |
CN105012993A (en) | Medical and antibacterial cationic biogel dressing and preparation method thereof | |
CN110384818B (en) | Alginate dressing | |
CN101564549A (en) | Traditional Chinese medicine dressing for antibacterium and hematischesis and production method thereof | |
CN105079863A (en) | Preparation method of aloe/sodium alginate double-layer hydrogel dressing | |
CN111481735A (en) | Medical antibacterial wound-protecting hydrogel dressing and preparation method thereof | |
CN109481148A (en) | A kind of moisture absorption vapor-permeable type wound dressing patch | |
CN103877606A (en) | Absorbable bleeding-stopping compound sponge and preparation method thereof | |
CN113663120B (en) | Hemostatic sponge cushion core and preparation method thereof | |
CN108969791B (en) | Composite wound dressing loaded with nano-silver and preparation method thereof | |
CN111073001A (en) | Amphoteric glucan hydrogel and application thereof | |
CN104771779A (en) | Functional dressing and preparation method thereof | |
CN104069535B (en) | A kind of Preparation method and use of biological activity composite membrane bleeding-stopping dressing | |
Ajith et al. | Natural polysaccharides for wound healing | |
US6251424B1 (en) | Wound dressing gel | |
US20200306289A1 (en) | Wound healing topical formulation and preparation thereof | |
CN111228562B (en) | Starch hemostatic sponge and preparation method and application thereof | |
JPS62129052A (en) | Wound covering material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |